Back to Stakeholders
Independent Academic Research GroupsHospitals

Psychiatric University Hospital, Zurich

Switzerland
4 Trials

The Psychiatric University Hospital Zurich (PUK) is affiliated with the University of Zurich and home to Franz Vollenweider's pioneering psychedelic neuroscience group, active since the 1990s; research includes PET imaging with psilocybin, S- and R-ketamine, MDMA, and DMT+harmine formulations, including a completed 2023 RCT of psilocybin (0.215 mg/kg) vs. placebo for major depressive disorder.

Quick Facts

Type
Other
HQ
Switzerland
Website
Visit

Sponsored Trials

3
CompletedI

Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects

Start Date
Compounds
DMT, Placebo
CompletedI

A Multimodal Neuroimaging Study of Brain Activation Patterns Under Ketamine

Start Date
Compounds
Ketamine, Placebo
CompletedNA

The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers

Start Date
Compounds
Placebo, LSD

Collaborated Trials

1
CompletedI

Molecular Imaging Study of Harmine/DMT: a Basic Research Approach (HaD-PET)

Start Date
Compounds
Ayahuasca, Placebo